Literature DB >> 15292102

Glu298Asp endothelial nitric oxide synthase polymorphism is a risk factor for erectile dysfunction in the Mexican Mestizo population.

Haydee Rosas-Vargas1, Ramon M Coral-Vazquez, Rosario Tapia, Jose L Borja, Ricardo A Salas, Fabio Salamanca.   

Abstract

Penile erection depends on the balanced action between antagonist vasoactive molecules such as nitric oxide (NO) and angiotensin. Endothelial nitric oxide synthase (eNOS) and angiotensin-converting enzyme (ACE) polymorphisms have been associated with endothelial dysfunction, which is described as a cause of erectile dysfunction (ED). Endothelial NOS and ACE are both regulators of vascular and corporal smooth muscle tone, which are connected by interaction between the NO-cyclic guanosine monophosphate pathway and the renin-angiotensin system. We analyzed the frequencies of 894 G/T (Glu298Asp) eNOS and ACE I/D polymorphisms in Mexican patients with ED (n=53) and in an age-matched control group (n=62). The populations analyzed were in Hardy Weinberg equilibrium. We found significant differences in allelic (chi2=4.42; P=.03) and genotypic frequencies (chi2=3.96; P=.04) between patients and controls for the 894 G/T eNOS polymorphism. Presence of the 894T allele in carriers increased the risk of ED (odds ratio [TT + GT versus GG] = 2.37; 95% confidence interval, 1.08 to 5.21; P=.02). Multiple logistic regression analysis showed that the Glu298Asp polymorphism was an independent factor for ED, as was diabetes mellitus, hypertension, cardiac disease, and cigarette smoking. No association was found between ACE I/D polymorphism and ED in the population studied. Therefore, our results suggest that Glu298Asp eNOS polymorphism plays a role as a genetic susceptibility factor for ED.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292102     DOI: 10.1002/j.1939-4640.2004.tb02847.x

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  9 in total

1.  Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population.

Authors:  Ana Branković; Goran Brajušković; Zorana Nikolić; Vinka Vukotić; Snežana Cerović; Dušanka Savić-Pavićević; Stanka Romac
Journal:  Int J Exp Pathol       Date:  2013-09-02       Impact factor: 1.925

Review 2.  [Single base polymorphisms and erectile dysfunction].

Authors:  A Eisenhardt; H Rübben; H Sperling
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

Review 3.  [Genetic aspects of erectile dysfunction].

Authors:  A Eisenhardt; H Sperling; H Rübben
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

Review 4.  Genetics of resistant hypertension: a novel pharmacogenomics phenotype.

Authors:  Nihal El Rouby; Rhonda M Cooper-DeHoff
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

5.  The demographic burden of urologic diseases in America.

Authors:  David C Miller; Christopher S Saigal; Mark S Litwin
Journal:  Urol Clin North Am       Date:  2009-02       Impact factor: 2.241

6.  Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms.

Authors:  Jaroslav Meluzín; Anna Vasků; Vladimír Kincl; Roman Panovský; Tat'ána Srámková
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

Review 7.  Sexual dysfunction in essential hypertension: myth or reality?

Authors:  Michael Doumas; Stella Douma
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738

Review 8.  Genetics and erectile dysfunction: leveraging early foundations for new discoveries.

Authors:  Darshan P Patel; Alexander W Pastuszak; James M Hotaling
Journal:  Int J Impot Res       Date:  2020-11-10       Impact factor: 2.896

Review 9.  Association of endothelial nitric oxide synthase polymorphisms with an increased risk of erectile dysfunction.

Authors:  Lei Gao; Zhifeng Zhao; Fengfu Guo; Yan Liu; Jianhua Guo; Yang Zhao; Zhong Wang
Journal:  Asian J Androl       Date:  2017 May-Jun       Impact factor: 3.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.